UPB — Upstream Bio, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2022626 ·
Last close
$2.10
Market Cap
$115.10M
52W High
$33.68
52W Low
$2.01
ADV30
1,359,163
Next earnings
2026-11-10
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 395,000 — -43,379,000 -41,192,000 245,992,000 47,416,000 12,017,000
Jun 2026 773,000 — -42,368,000 -39,702,000 281,171,000 79,397,000 10,214,000
Mar 2026 1,034,000 — -43,615,000 -40,591,000 318,054,000 96,724,000 14,059,000
Dec 2025 668,000 — -46,167,000 -42,459,000 353,772,000 101,578,000 14,001,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-168,334,000
Investing CF
$139,283,000
Financing CF
$4,303,000
CapEx
$-118,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.01
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-455,708,000
Inventory
—
Receivables
$1,468,000
ST Investments
$159,949,000
EBIT TTM
$-175,529,000
Pretax Income TTM
$-163,944,000
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,870,000
EBITDA
$-175,324,000
Free Cash Flow
$-114,344,624
Enterprise Value
$-54,200,332
Total Cash
$207,364,992
Total Debt
$789,000
Shares Out
54,811,391
Trailing EPS
$-3.01
Book Value
$4.27
ROE
-53.5%
ROA
-34.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,854,000 -160,361,000 -143,443,000 353,772,000 14,001,000 339,771,000 -133,275,000
Dec 2024 2,370,000 -77,764,000 -62,806,000 481,719,000 11,867,000 469,852,000 -59,172,000
Dec 2023 2,380,000 -40,114,000 -20,537,000 117,198,000 240,324,000 -123,126,000 -37,926,000
Dec 2022 1,212,000 -23,909,000 -23,868,000 18,478,000 124,633,000 -106,155,000 -19,021,000

TTM Snapshot

Revenues TTM
$3,158,000
NetIncome TTM
$-156,500,000
OpCashFlow TTM
—
Assets (Latest)
$281,171,000
Forward EPS
$-2.63

Peers — same industry

TickerNameMarket CapLastDaily %
SPRB SPRUCE BIOSCIENCES, INC. $116.37M $40.49 —
SCNX Scienture Holdings, Inc. $113.34M $2.76 —
AKBA Akebia Therapeutics, Inc. $111.18M $0.40 —
FHTX Foghorn Therapeutics Inc. $109.73M $1.83 —
NRXP NRX Pharmaceuticals, Inc. $106.07M $2.45 —

News headlines (Yahoo Finance, 1h cache)

Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates
2026-11-10 12:25 · Yahoo
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
2026-11-10 12:00 · Yahoo
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
2026-09-08 07:30 · Yahoo
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
2026-09-01 11:31 · Yahoo
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
2026-08-11 11:00 · Yahoo
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
2026-07-14 16:00 · Yahoo
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?
2026-06-23 15:36 · Yahoo
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 11:00 · Yahoo
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
2026-04-17 11:00 · Yahoo
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
2026-05-13 12:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.